Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GenSci143
- Development stage
- Phase 1
- Lead developer
- Changchun GeneScience Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**GenSci143** is a novel bispecific antibody-drug conjugate (BsADC) developed by Changchun GeneScience Pharmaceutical Co., Ltd., targeting **B7-H3 (CD276)** and **PSMA** (prostate-specific membrane antigen) on tumor cells. It comprises a bispecific antibody linked via a stable, cleavable linker to a potent **topoisomerase I (TOPO-I) inhibitor** payload. Upon binding, the conjugate internalizes into lysosomes, releasing the toxin to induce tumor cell death through targeted chemotherapy, with potential immune effects due to B7-H3 targeting. Preclinical data show superior antitumor efficacy in prostate cancer models versus single-target ADCs like DS-7300 (anti-B7-H3) and ARX517 (anti-PSMA), favorable pharmacokinetics, and tolerability in cynomolgus monkeys, addressing tumor heterogeneity in **metastatic castration-resistant prostate cancer (mCRPC)** and other solid tumors.[1][2][3][5]
- Other names
- B7H3 x PSMA ADCB-7H3 x PSMA ADCB 7H3 x PSMA ADC
02
Targets
TOP1 (DNA Topoisomerase I)B7-H3
Beyond the preview
Go deeper on GenSci143.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenSci143.